Circulating tumor DNA moves further into the spotlight

Assessment of somatic genomic alterations from tumors can now be performed by sequencing circulating tumor DNA from the cell-free component of blood. This procedure, which identifies tumor-derived somatic mutations from a simple blood sample, circumvents the need for tumor tissue. A recent study hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Sausen, Mark, Parpart, Sonya, Diaz, Luis A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062042/
https://www.ncbi.nlm.nih.gov/pubmed/24944584
http://dx.doi.org/10.1186/gm552
_version_ 1782321582930132992
author Sausen, Mark
Parpart, Sonya
Diaz, Luis A
author_facet Sausen, Mark
Parpart, Sonya
Diaz, Luis A
author_sort Sausen, Mark
collection PubMed
description Assessment of somatic genomic alterations from tumors can now be performed by sequencing circulating tumor DNA from the cell-free component of blood. This procedure, which identifies tumor-derived somatic mutations from a simple blood sample, circumvents the need for tumor tissue. A recent study highlights the promise of circulating tumor DNA to guide therapeutic decisions in a variety of solid tumors for both clinical and investigative purposes, as well as providing a tool for the early detection of cancer.
format Online
Article
Text
id pubmed-4062042
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40620422014-06-19 Circulating tumor DNA moves further into the spotlight Sausen, Mark Parpart, Sonya Diaz, Luis A Genome Med Research Highlight Assessment of somatic genomic alterations from tumors can now be performed by sequencing circulating tumor DNA from the cell-free component of blood. This procedure, which identifies tumor-derived somatic mutations from a simple blood sample, circumvents the need for tumor tissue. A recent study highlights the promise of circulating tumor DNA to guide therapeutic decisions in a variety of solid tumors for both clinical and investigative purposes, as well as providing a tool for the early detection of cancer. BioMed Central 2014-05-28 /pmc/articles/PMC4062042/ /pubmed/24944584 http://dx.doi.org/10.1186/gm552 Text en Copyright © 2014 Sausen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Sausen, Mark
Parpart, Sonya
Diaz, Luis A
Circulating tumor DNA moves further into the spotlight
title Circulating tumor DNA moves further into the spotlight
title_full Circulating tumor DNA moves further into the spotlight
title_fullStr Circulating tumor DNA moves further into the spotlight
title_full_unstemmed Circulating tumor DNA moves further into the spotlight
title_short Circulating tumor DNA moves further into the spotlight
title_sort circulating tumor dna moves further into the spotlight
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062042/
https://www.ncbi.nlm.nih.gov/pubmed/24944584
http://dx.doi.org/10.1186/gm552
work_keys_str_mv AT sausenmark circulatingtumordnamovesfurtherintothespotlight
AT parpartsonya circulatingtumordnamovesfurtherintothespotlight
AT diazluisa circulatingtumordnamovesfurtherintothespotlight

Ejemplares similares